to purging activity, such that high cellularity (10e8 cells/ml) results in a significant loss (65%) of T and B cells with only 1 hr coincubation, raising to 85-90% at a 6 hr co-incubation. Co-incubation at a log lower cellularity results in a 20-30% T-cell loss. ADCC is the primary purging mechanism; however, serum is required to retain cellular viability as is DNAse to reduce cellular clumping. Co-incubation temperature has little effect on purging, although cellular viability is higher at 4C compared to 37C. T, B and NK cells are sensitive to Alemtuzumab ADCC. DCs have a lower sensitivity and there is a differential sensitivity of DC subsets to alemtuzumab-mediated ADCC, such that CD123
ϩ DCs have a lower sensitivity as compared to the CD11c ϩ DCs. Further, immature myeloid suppressor cells (IMSCs) that are Lin -DR -CD11b ϩ or Lin -DR -CD14 -CD11b ϩ cells are refractory to alemtuzumab toxicity. This novel observation is of interest as IMSCs can induce T cell tolerance and thus have the potential to control GVHD. Critically, alemtuzumab purging of a hematopoietic stem cell products has no effect on CD34ϩ cell numbers and their (CFU-c) as assessed in vitro. To discern whether cord blood processing influences cord blood bank (CBB) inventory cell dose and CBT outcome, we (1) performed a large scale cell dose comparison of the NMDP CBBs that practice red cell depletion (RD) versus plasma depletion (PD), (2) performed an analysis comparing RD CBT results from an Institute of Medicine (IOM) study to audited outcome from a PD cord blood (CB) inventory, and (3) searched the literature for outcome of CBBs that practice PD and RD processing. Two of the CBBs in the NMDP network practice PD processing (nϭ10,912 CB) whereas all others practice RD (nϭ38,819 CB). PD processing results in less than 1% cell loss in the discarded fraction (excluding testing and archival samples), and various studies have reported different recovery rates for RD; however, no data exist for a rigorous comparison of actual inventories. Using data from NMDP's Cord Blood Bank Performance Report (6/30/06), the percentage of high cell dose units among the two types of CBBs were compared. Table 1A shows the proportion of CB with high TNC counts was significantly higher for PD CBU at all three levels (p Ͻ0.0001; test for difference in proportions). To our knowledge, this is the largest cell dose comparison of cord blood banks.
COMPARISON OF CELL DOSE AND OUTCOME FOR CORD BLOOD TRANSPLANTATION (CBT) SOURCED FROM PLASMA DEPLETED (PD) VERSUS RED CELL DEPLETED (RD) CORD BLOOD INVENTORIES
The IOM conducted a study that analyzed the outcome of 3 large CB inventories in order to find determinants of engraftment and patient survival (Gibbons 2005) . The IOM study used RD CB. All 205 patients transplanted with PD CB through 5/06 with survival and/or engraftment data were divided into three groups -alive, dead, and engraftment failure -which were then compared to the 755 transplants from the IOM study using identical methodologies (aliveϭengrafted & alive, deadϭengrafted & dead, and engraftment failureϭnever engrafted). Table 1B summarizes the proportion of patients in each category and chi-square test of homogeneity yielded a p-value of 0.002, suggesting that the PD CBT had a significantly higher proportion of survivors and lower proportion of engraftment failures.
Various cord blood bank studies from the literature were also summarized, which showed that transplants using PD CB may have higher cell doses than those using RD CB. Moreover, various RD CB inventories appeared to have similar outcome, which may be different from transplants using PD CB inventories though patient and disease profiles appear to match. During embryogenesis, Flk-1ϩ endothelial precursors contribute critically to the definitive onset of hematopoiesis. Adult sources of endothelial cells have also been shown to support the expansion of hematopoietic stem cells in vitro. However, the in vivo contribution of vascular endothelial cells to adult hematopoiesis has been less well characterized. In this study, we sought to determine whether transplantation of primary endothelial cells could enhance the hematopoietic recovery and survival of lethally irradiated mice. C57BL/6J mice were given sublethal (700 cGy) or lethal (1050 cGy) irradiation and subsequently transplanted with murine brainderived ECs (MBECs) or fetal blood-derived ECs (FBECs) for 5 days. Mice transplanted with MBECs alone demonstrated accelerated BM cellular recovery, radioprotection of BM c-kit ϩ sca-1 -lin -progenitors and enhanced regeneration of c-kit ϩ sca-1 ϩ lin -(KSL) stem/progenitor cells following irradiation compared to controls. MBEC transplantation also facilitated the recovery of circulating white blood cells and platelet counts following radiation exposure. Remarkably, 57% of mice transplanted with MBECs survived long-term (Ͼ60 days) following 1050 cGy irradiation, which was 100% lethal in control mice. Irradiated mice that were transplanted with FBECs also showed significantly increased survival, although these animals did not survive long-term. Conversely, transplantation with mesenchymal stem cells (MSCs) had no impact on the survival of irradiated mice, suggesting that an endothelial cell-specific activity accounted for the observed effects. These data suggest that vascular endothelial cells can mediate hematopoietic recovery following myeloablative injury and that transplantation of endothelial cells alone can improve the survival of lethally irradiated animals. Mesenchymal stem cells (MSC) are progenitor cells of stromal origin which can differentiate into multiple lineages. MSC also Poster Session I possess immunosuppressive properties by selectively halting immune cells at the G0-G1 phase of the cell cycle but only partially affecting their effector function (split anergy). For these reasons MSC have been used to manipulate graft-versus-host disease (GvHD). We tested the therapeutic potentials of human MSC to prevent and/or treat GvHD in a xenogeneic model. Sublethally irradiated NOD/SCID mice were transplanted with CFSE-labelled human PBMC obtained from normal buffy coats. In a group of mice MSC were given in a single infusion at the time of PBMC infusion whilst in another group MSC were administered at weekly intervals. Recipient mice were evaluated at serial intervals for human T cells proliferation as measured by CFSE staining and number of CD45ϩ/CD3ϩ cells; clinical signs of GvHD (wasting, ruffled hair, hunched back) were also monitored. At the end of the experiment lymphoid and non lymphoid tissues were examined by histological analysis. In control mice, the proliferation of human T cells was already evident in the peripheral blood 3 weeks after infusion and progressed thereafter. The mice started to develop signs of GvHD after 8-10 weeks and the disease was then confirmed by histology. Lymphoid infiltrates were evident in lymphoid tissues as well as in liver, kidney, spleen, lung, and peritoneal washing. The mice injected with a single dose of MSC at the time of PBMC infusion did not behave differently form the controls. However, when MSC were given at weekly intervals, there was a marked decrease in human T cell engraftment and none of the mice developed GvHD. If MSC were administered when GvHD had already developed, T cell expansion and the course of the disease were comparable to controls. MSC were tracked 10 days after infusion by using cells which had been transduced with eGFP. PCR analysis showed their presence only in the BM in mice receiving only PBMC, but were distributed also in the lungs, liver and peritoneal washing in the mice in which MSC were administered with PBMC. Our study shows that the frequent administrations of MSC prevent the development of GVHD but fails to treat the disease when established. These findings are consistent with the notion that the immunosuppressive effect of MSC resembles split anergy, thus supporting the use of MSC as a prophylactic rather than a therapeutic agent for GvHD.
Cell Dose & Outcome Comparison Between PD & RD CB Inventories

MESENCHYMAL STEM CELLS ARE EFFECTIVE AT PREVENTING BUT NOT AT TREATING GVJD
